News

Deal Announcements

Avaxia Biologics Closes Series B Venture Capital

Friday, June 7, 2013 5:35:00 AM PDT | VentureDeal
   Lexington, Massachusetts  --  Biotechnology company Avaxia Biologics has secured $11.4 million in its second round of venture capital investment.

Avaxia is developing oral antibody products for diseases that can be treated through the mouth and the gastrointestinal tract.

A large syndicate of angel groups made the investment.

The company will use the proceeds to advance the clinical development of its treatment for inflammatory bowel disease, AVX-470.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1